Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma

Anti-Cancer Drugs

Volumn 11, Issue 8, 2000, Pages 635-638

  Oettle, Helmut ^a,c   Arnold, Dirk ^a   Esser, Martin ^b   Huhn, Dieter ^a   Riess, Hanno ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Krankenhaus Grevenbroich   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Advanced pancreatic carcinoma; Paclitaxel; Pretreatment with gemcitabine; Salvage therapy; Weekly schedule

Indexed keywords

FLUOROURACIL; FOLIC ACID; FOLINATE CALCIUM; GEMCITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; FEMALE; HUMAN; LEUKOPENIA; LIVER TOXICITY; MALE; PANCREAS CARCINOMA; PRIORITY JOURNAL; REMISSION;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PANCREATIC NEOPLASMS; PROGNOSIS; QUALITY OF LIFE; SALVAGE THERAPY;

EID: 0033783410     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200009000-00006     Document Type: Article

References (10)

1. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: A randomized trial
2. Phase I study of a treatment with gemcitabine and docetaxel weekly in advanced pancreatic cancer
3. Phase I trial of gemcitabine (Gemzar®), 24-hour infusion of 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer
4. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents
5. Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: A multicenter phase II study
6. Single agent paclitaxel in the treatment of unresectable and/or metastatic pancreatic adenocarcinoma
7. Weekly taxanes in treatment of metastatic breast cancer
8. A large phase II study of paclitaxel administerd as a weekly one hour infusion in patients with metastatic breast cancer
9. Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: Result of a phase I/II study
10. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer